Clinical Trials Logo
  1. Home
  2. H1N1 Influenza
  3. NCT01008683
  4. Details
NCT01008683 Clinical Trial

Antibody Production Following H1N1 Influenza Vaccination After Stem Cell and Heart Transplantation

H1N1 Influenza Clinical Trial

Official title:
Antibody Production Following H1N1 Influenza Vaccination After Stem Cell and Heart Transplantation

Clinical Trial Details — Status: Recruiting

Administrative data
NCT number NCT01008683
Other study ID # engelhard-HMO-CTIL
Secondary ID
Status Recruiting
Phase N/A
First received November 5, 2009
Last updated November 5, 2009
Start date November 2009
Est. completion date July 2010

Study information
Verified date November 2009
Source Hadassah Medical Organization
Contact Hadas Lemberg
Email lhadas@hadassah.org.il
Is FDA regulated No
Health authority Israel: Ministry of Health
Study type Observational

Clinical Trial Summary

Stem cell and and heart transplant patients will receive pandemic H1N1 influenza vaccination according to the clinical guidelines.

In these patients the investigators will measure the specific antibody production.

Description:

Stem cell and and heart transplant patients will receive pandemic H1N1 influenza vaccination according to the clinical guidelines. Two doses will be given, in 3-week interval.

In these patients we will measure the specific antibody production. Blood sample 5 ml will be drawn before the first vaccine, before the second, and 3-4 weeks after the 2nd dose.

Recruitment information / eligibility
Status Recruiting
Enrollment 300
Est. completion date July 2010
Est. primary completion date April 2010
Accepts healthy volunteers No
Gender Both
Age group N/A to 80 Years
Eligibility Inclusion Criteria:

- Stem cell and and heart transplant patients who will receive pandemic H1N1 influenza vaccination according to the clinical guidelines.

Exclusion Criteria:

- Patients with unstable grafts.

Study Design

Time Perspective: Prospective

Related Conditions & MeSH terms

Locations
Country Name City State
Israel Hadassah Medical Organization Jerusalem

Sponsors (1)
Lead Sponsor Collaborator
Hadassah Medical Organization

Country where clinical trial is conducted

Israel, 

See also
  Status Clinical Trial Phase
Completed NCT03641690 - Serum and Bronchoalveolar Inflammatory Parameters in Patients With Severe Adult Respiratory Distress Syndrome
Terminated NCT00970606 - STIP: Statin Trial for Influenza Patients N/A
Completed NCT02921997 - H7N9 Vaccination With and Without AS03 and Unadjuvanted H3N2v Vaccination: Standard and Systems Biology Analyses Phase 2
Completed NCT01011582 - Characteristics and Outcomes of Intensive Care Unit Patients Admitted With Novel H1N1 Influenza or Seasonal Influenza N/A
Active, not recruiting NCT01421251 - H1N1 Vaccine Safety in Manitoba, Canada N/A
Recruiting NCT04497311 - Tomographic Findings in COVID-19 and Influenza
Completed NCT04933994 - Comparison of COVID-19 and H1N1 Influenza Pneumonia
Completed NCT01002040 - Rapid Evaluation of Pandemic H1N1 Influenza Vaccine in Adults With HIV Phase 4
Terminated NCT01798602 - Collaborative H1N1 Adjuvant Treatment (CHAT) Pilot Trial Phase 2
Unknown status NCT01127282 - The Impact of Vitamin on the Clinical Course in Cases Infected by Novel H1N1 Influenza Virus A Phase 4
Terminated NCT04810949 - Vitamine D3 Supplementation in Patients With Serum Values +/- 20ng/ml N/A
Completed NCT05080933 - ECMO for COVID-19 vs Influenza A H1N1 Associated ARDS